In the context of inflammation, ROCK2 inhibitor KD025 previously has been shown to suppress the production of IL17A, IL-10, and IL-21 by human T-cells via the STAT3-dependent mechanism,76,97 and a phase-2 clinical trial for its application for psoriasis vulgaris has been recently completed (clinicaltrials.govNCT02317627). This evidence concerns the gene IL17A and psoriasis vulgaris.